Short Interest in Daxor Corporation (NASDAQ:DXR) Decreases By 44.0%

Daxor Corporation (NASDAQ:DXR) saw a large decline in short interest during the month of February. As of February 13th, there was short interest totaling 3,761 shares, a decline of 44.0% from the January 29th total of 6,713 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average daily volume of 6,480 shares, the days-to-cover ratio is currently 0.6 days. Based on an average daily volume of 6,480 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.2% of the company’s shares are sold short.

Daxor Price Performance

Shares of Daxor stock traded down $0.09 on Friday, reaching $11.86. The company had a trading volume of 517 shares, compared to its average volume of 5,659. The firm’s 50 day moving average price is $13.10 and its two-hundred day moving average price is $12.62. Daxor has a 52-week low of $7.10 and a 52-week high of $14.76.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Daxor stock. Osaic Holdings Inc. acquired a new stake in Daxor Corporation (NASDAQ:DXR) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 8,750 shares of the company’s stock, valued at approximately $86,000. Osaic Holdings Inc. owned approximately 0.18% of Daxor at the end of the most recent quarter. 1.34% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on DXR. Lake Street Capital initiated coverage on shares of Daxor in a report on Wednesday, February 11th. They set a “buy” rating for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Daxor in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.00.

Daxor Company Profile

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.